The present invention relates to cyclic cyanoenone derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and m are as defined herein. The present invention also relates to pharmaceutical compositions comprising the cyclic cyanoenone derivatives of Formula (I) and to their use in therapy.

##STR00001##

The present invention relates to cyclic cyanoenone derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and m are as defined herein. The present invention also relates to pharmaceutical compositions comprising the cyclic cyanoenone derivatives of Formula (I) and to their use in therapy.

##STR00001##

The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of central inflammatory diseases, or a pharmacologically acceptable salt thereof. The present invention addresses a compound of a general formula (I) or a pharmacologically acceptable salt thereof as a means to solve the problem. [R.sup.1: a C1-C6 alkyl group or the like, R.sup.2: a C1-C6 alkyl group or the like, A: a 5-membered aromatic hetero-ring or the like, R.sup.3, R.sup.3′: a C1-C6 alkyl group or the like]

The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of central inflammatory diseases, or a pharmacologically acceptable salt thereof. The present invention addresses a compound of a general formula (I) or a pharmacologically acceptable salt thereof as a means to solve the problem. [R.sup.1: a C1-C6 alkyl group or the like, R.sup.2: a C1-C6 alkyl group or the like, A: a 5-membered aromatic hetero-ring or the like, R.sup.3, R.sup.3′: a C1-C6 alkyl group or the like]

The invention provides compounds of formula (I): ##STR00001## Said compounds being modulators of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

The invention provides compounds of formula (I): ##STR00001## Said compounds being modulators of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of central inflammatory diseases, or a pharmacologically acceptable salt thereof. The present invention addresses a compound of a general formula (I) or a pharmacologically acceptable salt thereof as a means to solve the problem. [R.sup.1: a C1-C6 alkyl group or the like, R.sup.2: a C1-C6 alkyl group or the like, A: a 5-membered aromatic hetero-ring or the like, R.sup.3, R.sup.3′: a C1-C6 alkyl group or the like.

The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of central inflammatory diseases, or a pharmacologically acceptable salt thereof. The present invention addresses a compound of a general formula (I) or a pharmacologically acceptable salt thereof as a means to solve the problem. [R.sup.1: a C1-C6 alkyl group or the like, R.sup.2: a C1-C6 alkyl group or the like, A: a 5-membered aromatic hetero-ring or the like, R.sup.3, R.sup.3′: a C1-C6 alkyl group or the like.

The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts.

The present disclosure provides compositions and methods for metathesizing a first alkenyl or alkynyl group with a second alkenyl or alkynyl group, the composition comprising a ruthenium metathesis catalyst and a photoredox catalyst that is activated by visible light.